ErbB3 targeting enhances the effects of MEK inhibitor in wild-type BRAF/NRAS melanoma

MEK-ERK1/2 signaling is elevated in melanomas that are wild-type for both BRAF and NRAS (WT/WT), but patients are insensitive to MEK inhibitors. Stromal-derived growth factors may mediate resistance to targeted inhibitors, and optimizing the use of targeted inhibitors for WT/WT melanoma patients is...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Res
Päätekijät: Capparelli, Claudia, Purwin, Timothy J., Heilman, Shea A., Chervoneva, Inna, McCue, Peter A., Berger, Adam C., Davies, Michael A., Gershenwald, Jeffrey E., Krepler, Clemens, Aplin, Andrew E.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2018
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6168374/
https://ncbi.nlm.nih.gov/pubmed/30115691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-18-1001
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia